Microtest Laboratories will manufacture ImmusanT, Inc.’s Nexvax2 immunotherapeutic vaccine for its expected upcoming clinical trial. In addition to manufacturing Nexvax2, Microtest will provide a full range of testing services to ImmusanT, supporting drug product manufacture, including method transfer activities, complete final product release testing, storage and stability.   Nexvax2 is being investigated for the treatment of celiac disease, an inherited autoimmune disorder that is triggered by...